Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Iveta Kudaba"'
Autor:
Gilberto de Castro, Iveta Kudaba, Yi-Long Wu, Gilberto Lopes, Dariusz M. Kowalski, Hande Z. Turna, Christian Caglevic, Li Zhang, Boguslawa Karaszewska, Konstantin K. Laktionov, Vichien Srimuninnimit, Igor Bondarenko, Kaoru Kubota, Rinee Mukherjee, Jianxin Lin, Fabricio Souza, Tony S.K. Mok, Byoung Chul Cho
Publikováno v:
Journal of Clinical Oncology. 41:1986-1991
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co‐primary or secondary analyses are not yet available. Clinical
Autor:
Zev A. Wainberg, Kohei Shitara, Eric Van Cutsem, Lucjan Wyrwicz, Keun Wook Lee, Iveta Kudaba, Marcelo Garrido, Hyun Cheol Cheol Chung, Jeeyun Lee, Hugo Raul Castro-Salguero, Wasat Mansoor, Maria Ignez Braghiroli, Nina Karaseva, Eray Goekkurt, Hironaga Satake, Joseph Chao, Uma Kher, Sukrut Shah, Pooja Bhagia, Josep Tabernero
Publikováno v:
Journal of Clinical Oncology. 40:243-243
243 Background: KEYNOTE-062 (NCT02494583) is a global phase 3 study of pembrolizumab (pembro) as monotherapy and in combination with chemotherapy (chemo) versus chemo as first-line therapy for PD-L1–positive (combined positive score [CPS] ≥1) adv
Autor:
Soonmo Peter Kang, Marcelo Garrido, Hyun Cheol Chung, Lucjan Wyrwicz, Iveta Kudaba, Sukrut Shah, Zev A. Wainberg, Wasat Mansoor, Kohei Shitara, Charles S. Fuchs, Joseph Chao, Uma Kher, Keun Wook Lee, Yung-Jue Bang, Eray Goekkurt, Eric Van Cutsem, Hugo Raul Castro Salguero, Maria Ignez Braghiroli, Josep Tabernero
Publikováno v:
Journal of Clinical Oncology. 37:LBA4007-LBA4007
LBA4007 Background: KEYNOTE062 (NCT02494583) was a randomized, active controlled study of 1L P or P+C vs C in pts with PD-L1 combined positive score ≥1 (CPS ≥1), HER2-negative, advanced GC. Methods: Eligible pts were randomized 1:1:1 to P 200 mg
Autor:
Yi-Long Wu, Gilberto de Castro, Dariusz M. Kowalski, Kaoru Kubota, Debra Kush, Igor Bondarenko, Gilberto Lopes, Vichien Srimuninnimit, Gregory M. Lubiniecki, Tony Mok, Byoung Chul Cho, Iveta Kudaba, Jin Zhang
Publikováno v:
ResearcherID
LBA4 Background: In KEYNOTE-024, pembro significantly improved PFS (primary end point) and OS (secondary end-point) over chemo as first-line therapy for metastatic NSCLC without targetable alterations and PD-L1 TPS ≥50%. In KEYNOTE-042, we compared